164 related articles for article (PubMed ID: 16533159)
1. From the design to the clinical application of thromboxane modulators.
Dogné JM; Hanson J; de Leval X; Pratico D; Pace-Asciak CR; Drion P; Pirotte B; Ruan KH
Curr Pharm Des; 2006; 12(8):903-23. PubMed ID: 16533159
[TBL] [Abstract][Full Text] [Related]
2. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators.
Dogné JM; de Leval X; Hanson J; Frederich M; Lambermont B; Ghuysen A; Casini A; Masereel B; Ruan KH; Pirotte B; Kolh P
Curr Med Chem; 2004 May; 11(10):1223-41. PubMed ID: 15134516
[TBL] [Abstract][Full Text] [Related]
3. Thromboxane synthase inhibitors and thromboxane A2 receptor antagonists: a quantitative structure activity relationships (QSARs) analysis.
Kontogiorgis C; Hadjipavlou-Litina D
Curr Med Chem; 2010; 17(28):3162-214. PubMed ID: 20666724
[TBL] [Abstract][Full Text] [Related]
4. Thromboxane A Synthase: A New Target for the Treatment of Cardiovascular Diseases.
Mesitskaya DF; Syrkin AL; Aksenova MG; Zhang Y; Zamyatnin AA; Kopylov PY
Cardiovasc Hematol Agents Med Chem; 2018; 16(2):81-87. PubMed ID: 30039765
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
Vezza R; Mezzasoma AM; Venditti G; Gresele P
Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
[TBL] [Abstract][Full Text] [Related]
6. Antiplatelet therapy: targeting the TxA2 pathway.
Fontana P; Zufferey A; Daali Y; Reny JL
J Cardiovasc Transl Res; 2014 Feb; 7(1):29-38. PubMed ID: 24353037
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents.
de Leval X; Dassesse T; Dogné JM; Waltregny D; Bellahcène A; Benoit V; Pirotte B; Castronovo V
J Pharmacol Exp Ther; 2006 Sep; 318(3):1057-67. PubMed ID: 16720756
[TBL] [Abstract][Full Text] [Related]
8. Prostanoids as pharmacological targets in COPD and asthma.
Rolin S; Masereel B; Dogné JM
Eur J Pharmacol; 2006 Mar; 533(1-3):89-100. PubMed ID: 16458293
[TBL] [Abstract][Full Text] [Related]
9. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
[TBL] [Abstract][Full Text] [Related]
10. New trends in thromboxane and prostacyclin modulators.
Dogné JM; de Leval X; Delarge J; David JL; Masereel B
Curr Med Chem; 2000 Jun; 7(6):609-28. PubMed ID: 10702629
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological evaluation of both enantiomers of (R,S)-BM-591 as thromboxane A2 receptor antagonists and thromboxane synthase inhibitors.
Rolin S; Dogne JM; Vastersaegher C; Hanson J; Masereel B
Prostaglandins Other Lipid Mediat; 2004 Oct; 74(1-4):75-86. PubMed ID: 15560117
[TBL] [Abstract][Full Text] [Related]
12. The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis.
Ekambaram P; Lambiv W; Cazzolli R; Ashton AW; Honn KV
Cancer Metastasis Rev; 2011 Dec; 30(3-4):397-408. PubMed ID: 22037941
[TBL] [Abstract][Full Text] [Related]
13. New developments on thromboxane modulators.
Dogné JM; Hanson J; de Leval X; Masereel B; Kolh P; Pirotte B
Mini Rev Med Chem; 2004 Aug; 4(6):649-57. PubMed ID: 15279599
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation.
de Leval X; Benoit V; Delarge J; Julémont F; Masereel B; Pirotte B; Merville MP; David JL; Dogné JM
Prostaglandins Leukot Essent Fatty Acids; 2003 Jan; 68(1):55-9. PubMed ID: 12538091
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet effect of NQ12: a possible mechanism through the arachidonic acid cascade.
Jin YR; Han XH; Lee JJ; Lim Y; Kim TJ; Yoo HS; Hong JT; Lee CK; Yun YP
J Pharmacol Sci; 2007 Oct; 105(2):193-200. PubMed ID: 17951980
[TBL] [Abstract][Full Text] [Related]
16. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function.
Dogné JM; de Leval X; Kolh P; Sanna V; Rolin S; Michaux C; Mauer M; David JL; Masereel B; Pirotte B
Prostaglandins Leukot Essent Fatty Acids; 2003 Jan; 68(1):49-54. PubMed ID: 12538090
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers.
Tello-Montoliu A; Rollini F; Desai B; Pasqualino G; Patel R; Sorensen AS; Sakariassen KS; Angiolillo DJ
J Thromb Thrombolysis; 2012 Oct; 34(3):297-9. PubMed ID: 22923024
[No Abstract] [Full Text] [Related]
19. In vitro platelet antiaggregatory properties of 4-methylcoumarins.
Macáková K; Řeháková Z; Mladěnka P; Karlíčková J; Filipský T; Říha M; Prasad AK; Parmar VS; Jahodář L; Pávek P; Hrdina R; Saso L
Biochimie; 2012 Dec; 94(12):2681-6. PubMed ID: 22996069
[TBL] [Abstract][Full Text] [Related]
20. Mechanism for antiplatelet effect of onion: AA release inhibition, thromboxane A(2)synthase inhibition and TXA(2)/PGH(2)receptor blockade.
Moon CH; Jung YS; Kim MH; Lee SH; Baik EJ; Park SW
Prostaglandins Leukot Essent Fatty Acids; 2000 May; 62(5):277-83. PubMed ID: 10883058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
